Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.

Pizzamiglio, S; Ciniselli, C M; de Azambuja, E; Agbor-Tarh, D; Moreno-Aspitia, A; Suter, T M; Trama, A; De Santis, M C; De Cecco, L; Iorio, M V; Silvestri, M; Pruneri, G; Verderio, P; Di Cosimo, S (2024). Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO. Breast cancer research and treatment, 206(2), pp. 285-294. Springer 10.1007/s10549-024-07299-6

[img]
Preview
Text
s10549-024-07299-6.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

PURPOSE

The relevance of cardiotoxicity in the context of HER2-positive breast cancer is likely to increase with increasing patient treatment exposure, number of treatment lines, and prolonged survival. Circulating biomarkers to early identify patients at risk of cardiotoxicity could allow personalized treatment and follow-up measures. The aim of this study is to examine the relationship between circulating microRNAs and adverse cardiac events in HER2-positive breast cancer patients.

METHODS

We based our work on plasma samples from NeoALTTO trial obtained at baseline, after 2 weeks of anti-HER2 therapy, and immediately before surgery. Eleven patients experienced either a symptomatic or asymptomatic cardiac event. Circulating microRNAs were profiled in all patients presenting a cardiac event (case) and in an equal number of matched patients free of reported cardiac events (controls) using microRNA-Ready-to-Use PCR (Human panel I + II). Sensitivity analyses were performed by increasing the number of controls to 1:2 and 1:3. Normalized microRNA expression levels were compared between cases and controls using the non-parametric Kruskal-Wallis test.

RESULTS

Eight circulating microRNAs resulted differentially expressed after 2 weeks of anti-HER2 therapy between patients experiencing or not a cardiac event. Specifically, the expression of miR-125b-5p, miR-409-3p, miR-15a-5p, miR-423-5p, miR-148a-3p, miR-99a-5p, and miR-320b increased in plasma of cases as compared to controls, while the expression of miR-642a-5p decreases. Functional enrichment analysis revealed that all these microRNAs were involved in cardiomyocyte adrenergic signaling pathway.

CONCLUSION

This study provides proof of concept that circulating microRNAs tested soon after treatment start could serve as biomarkers of cardiotoxicity in a very early stage in breast cancer patients receiving anti-HER2 therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Suter, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-6806

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

01 May 2024 10:13

Last Modified:

19 Jun 2024 00:16

Publisher DOI:

10.1007/s10549-024-07299-6

PubMed ID:

38689174

Uncontrolled Keywords:

Breast cancer Cardiotoxicity Circulating microRNA HER2 miRNAs

BORIS DOI:

10.48350/196419

URI:

https://boris.unibe.ch/id/eprint/196419

Actions (login required)

Edit item Edit item
Provide Feedback